Cadila Healthcare moves up on getting USFDA nod for Ethacrynate Sodium for Injection USP

20 Nov 2017 Evaluate

Cadila Healthcare is currently trading at Rs. 450.00, up by 3.65 points or 0.82% from its previous closing of Rs. 446.35 on the BSE.

The scrip opened at Rs. 450.55 and has touched a high and low of Rs. 453.70 and Rs. 448.05 respectively. So far 20017 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 329.95 on 26-Dec-2016.

Last one week high and low of the scrip stood at Rs. 468.90 and Rs. 436.80 respectively. The current market cap of the company is Rs. 46114.49 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.28% and 7.93% respectively.

Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Ethacrynate Sodium for Injection USP, 50 mg/vial. The drug is used to decrease the swelling (edema) caused by various disease conditions such as liver disease, kidney disease, congestive heart failure, cancer etc. and will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×